Literature DB >> 12354365

Management of angiosarcoma.

G Thomas Budd1.   

Abstract

Angiosarcoma is an uncommon tumor that presents in several scenarios. Although angiosarcoma can occur in any organ, it typically presents in the following settings: 1) in the face or scalp among elderly patients, 2) with chronic lymphedema, 3) after radiotherapy, or 4) as a hepatic primary. In all of these situations, angiosarcoma is associated with multifocality and an insidious growth pattern, making local control difficult. Doxorubicin-ifosfamide chemotherapy produces a modest response rate, and paclitaxel appears to be useful for scalp and facial angiosarcomas. However, improvement in systemic therapy is clearly needed. One logical strategy is to investigate antiangiogenic therapies in this endothelial tumor. Improved therapy for this tumor will come only with greater understanding of its biology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354365     DOI: 10.1007/s11912-002-0066-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  48 in total

1.  The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.

Authors:  Bruce A Ruggeri; Candy Robinson; Thelma Angeles; John Wilkinson; Margie L Clapper
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

2.  The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice.

Authors:  J L Arbiser; D Panigrathy; N Klauber; M Rupnick; E Flynn; T Udagawa; R J D'Amato
Journal:  J Am Acad Dermatol       Date:  1999-06       Impact factor: 11.527

3.  Angiogenesis does not correlate with prognosis or expression of vascular endothelial growth factor in synovial sarcomas.

Authors:  S Kawauchi; T Fukuda; M Tsuneyoshi
Journal:  Oncol Rep       Date:  1999 Sep-Oct       Impact factor: 3.906

4.  Angiosarcoma of the scalp and face: failure of an interferon alpha treatment.

Authors:  B Guillot; N Raison-Peyron; M Acevedo; L Meunier; M Dandurand; J Meynadier
Journal:  Eur J Dermatol       Date:  2000-06       Impact factor: 3.328

5.  Angiosarcoma treated with radiotherapy: impact of tumor type and size on outcome.

Authors:  Ryohei Sasaki; Toshinori Soejima; Kazushi Kishi; Yoshinari Imajo; Saeko Hirota; Norihiko Kamikonya; Masao Murakami; Tetsuya Kawabe; Yasuo Ejima; Akira Matsumoto; Kazuo Sugimura
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-15       Impact factor: 7.038

6.  Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.

Authors:  R A Brekken; J P Overholser; V A Stastny; J Waltenberger; J D Minna; P E Thorpe
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

7.  Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470.

Authors:  T Kalebic; M Tsokos; L J Helman
Journal:  Int J Cancer       Date:  1996-11-27       Impact factor: 7.396

8.  Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Authors:  R A Ezekowitz; J B Mulliken; J Folkman
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

9.  MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas.

Authors:  C Zietz; M Rössle; C Haas; A Sendelhofert; A Hirschmann; M Stürzl; U Löhrs
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

10.  Angiogenesis in malignant fibrous histiocytoma.

Authors:  M Ohsawa; Y Tomita; S Kuratsu; H Kanno; K Aozasa
Journal:  Oncology       Date:  1995 Jan-Feb       Impact factor: 2.935

View more
  26 in total

1.  Orthopaedic case of the month: A 30-year-old woman with a painful forearm mass.

Authors:  J Hochfelder; L D Rybak; R Garcia; J C Wittig
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

2.  [Livid-colored tumor on the scalp].

Authors:  U W Neisius; G Schuler; M Lüftl
Journal:  Hautarzt       Date:  2005-08       Impact factor: 0.751

3.  Stewart Treves Syndrome: A Case Report.

Authors:  Ali Güleç; Harun Kütahya; Nazım Karalezli; Burkay Kacira; M Ali Acar
Journal:  Oman Med J       Date:  2014-03

4.  ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model.

Authors:  Stephanie E Busch; Kay E Gurley; Russell D Moser; Christopher J Kemp
Journal:  J Pathol       Date:  2012-05-08       Impact factor: 7.996

Review 5.  [Primary sarcomas and sarcoma metastases in the liver: morphological and molecular aspects].

Authors:  G Mechtersheimer; R Penzel; W J Hofmann; P Schirmacher
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

6.  [Clinical and immunohistochemical findings of intra- and extraoral angiosarcomas].

Authors:  Oliver Driemel; A Berndt; A Hartmann; U D Mueller-Richter; R Bauer; T E Reichert; H Kosmehl
Journal:  Mund Kiefer Gesichtschir       Date:  2006-07

Review 7.  Advances in the systemic treatment of cutaneous sarcomas.

Authors:  Jason J Luke; Mary Louise Keohan
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

8.  Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification.

Authors:  I Yonezawa; M Waki; Y Tamura; R Onoda; M Narushima; T Ishizuka; S Tajima
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

9.  Clinical management of secondary angiosarcoma after breast conservation therapy.

Authors:  Martina Zemanova; Katarina Machalekova; Monika Sandorova; Elena Boljesikova; Marta Skultetyova; Juraj Svec; Andrej Zeman
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-23

10.  Intraosseous angiosarcoma with secondary aneurysmal bone cysts presenting as an elusive diagnostic challenge.

Authors:  Lung Fung Tse; Eugene Th Ek; John L Slavin; Stephen M Schlicht; Peter Fm Choong
Journal:  Int Semin Surg Oncol       Date:  2008-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.